Hemogenyx Pharmaceuticals (LSE:HEMO) 3-Year EBITDA Growth Rate : -2.50% (As of Jun. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Hemogenyx Pharmaceuticals 3-Year EBITDA Growth Rate?

Hemogenyx Pharmaceuticals's EBITDA per Share for the six months ended in Jun. 2024 was £-0.77.

During the past 3 years, the average EBITDA Per Share Growth Rate was -2.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -0.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Hemogenyx Pharmaceuticals was 19.70% per year. The lowest was -258.40% per year. And the median was 0.00% per year.

Competitive Comparison of Hemogenyx Pharmaceuticals's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Hemogenyx Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemogenyx Pharmaceuticals's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemogenyx Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Hemogenyx Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.

Save Embed

;

Save Embed

;

Hemogenyx Pharmaceuticals 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Hemogenyx Pharmaceuticals (LSE:HEMO) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Hemogenyx Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Hemogenyx Pharmaceuticals's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Hemogenyx Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemogenyx Pharmaceuticals PLC (LSE:HEMO) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Heddon Street, London, GBR, W1B 4BT

Website

https://www.hemogenyx.com

Hemogenyx Pharmaceuticals PLC is a clinical-stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. The company is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.

Hemogenyx Pharmaceuticals Headlines

No Headlines